title: Intrinsic procoagulant surface induced by hypercholesterolaemia on rabbit aortic endothelium.
abstract: The effect of hyperlipidaemia on endothelial cell haemostatic properties was examined using ex vivo studies on aortic segments obtained from fat-fed Chinchilla rabbits, mounted in a template device which exposed the luminal surface. Exposure of arterial endothelium to lipids resulted in marked enhancement of externally exposed anionic phospholipids, detected using either fluorescence microscopy with the probe merocyanine 540 or by binding of 125I-polymyxin B and 125I-Annexin V. Consistent with the known procoagulant properties of anionic phospholipid, following the lipid and cholesterol-rich diet intake, intact endothelial cells demonstrated enhanced binding of radioiodinated factors IX/IXa and Xa, and enhanced factor IXa/VIII-dependent factor X activation and factor Xa-factor Va-mediated prothrombin activation. Both factor Xa and thrombin formation were blocked, in large part, by polymyxin B, suggesting dependence of the reaction on anionic phospholipids. Consistent with these results, evidence of increased activation of the coagulation mechanism in vivo was observed in hyperlipidaemic animals, as assessed by a three-fold increase in levels of circulating antithrombin-protease complexes, compared with normolipidaemic controls.
authors.affiliation: Institute of Cellular Biology and Pathology, Bucharest, Romania.
authors.forename: F
authors.initials: F
authors.lastname: Lupu
authors.forename: N
authors.initials: N
authors.lastname: Moldovan
authors.forename: J
authors.initials: J
authors.lastname: Ryan
authors.forename: D
authors.initials: D
authors.lastname: Stern
authors.forename: N
authors.initials: N
authors.lastname: Simionescu
mesh_terms: D000818:Animals; D000838:Anions; D017304:Annexin A5 / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism; D001011:Aorta / Q000378:metabolism; D001779:Blood Coagulation Factors / Q000378:metabolism*; D002791:Cholesterol, Dietary / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D005164:Factor IX / Q000378:metabolism; D015949:Factor IXa / Q000378:metabolism / Q000494:pharmacology; D005169:Factor VIII / Q000494:pharmacology; D015943:Factor Va / Q000494:pharmacology; D005170:Factor X / Q000378:metabolism; D015951:Factor Xa / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000378:metabolism*; D008055:Lipids / Q000494:pharmacology; D008297:Male; D008856:Microscopy, Fluorescence; D010743:Phospholipids / Q000378:metabolism; D011112:Polymyxin B / Q000378:metabolism; D011516:Prothrombin / Q000378:metabolism; D011817:Rabbits
chemical_list: D000838:Anions; D017304:Annexin A5; D001779:Blood Coagulation Factors; D002791:Cholesterol, Dietary; D008055:Lipids; D010743:Phospholipids; D015943:Factor Va; D000990:Antithrombin III; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D015949:Factor IXa; D015951:Factor Xa; D011112:Polymyxin B